DRG Epidemiology's coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of schizophrenia for each country, as well as annualized case counts projected to the national population.

Table of contents

  • Schizophrenia - Epidemiology - Americas
    • Introduction
      • Key Findings
        • Prevalence of Schizophrenia per 1,000 Among Adults in 2016 and 2026
        • Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Schizophrenia over the Next Ten Years
        • Analysis of the Prevalent Cases of Schizophrenia in 2016 by Cognitive Impairment Status
    • Epidemiology Data
    • Methods
      • Diagnosed Prevalent Cases
      • Diagnosed Incident Cases
      • Positive and Negative Symptom Status
      • Comorbid Cognitive Impairment
      • Percentage Drug-Treated
      • Lifetime DALYs Gained
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Schizophrenia
        • Studies Excluded from the Analysis of Schizophrenia
      • Risk/Protective Factors
        • Risk/Protective Factors for Schizophrenia
      • Bibliography

    Author(s): Nishant Kumar, MPH; Swarali Tadwalkar

    Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.

    His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.

    Swarali joined Decision Resources Group (DRG) in 2016 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with her particular interests in the oncology space.

    Prior to joining DRG, she has been extensively involved in primary and secondary healthcare research. Her experience involves projects in digital health, health policy and management, and health economics and outcomes research (HEOR). She has also coordinated various non-governmental public health projects focusing in hepatitis and human papilloma virus treatment access. Swarali holds a Masters in Public Health (Epidemiology) degree from the University of South Florida, Tampa.


    Related Reports

    Schizophrenia - Landscape & Forecast - Disease Landscape And Forecast G7

    The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) are al...

    View Details

    Schizophrenia| Disease Landscape and Forecast | G7 | 2020

    The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) are also ava...

    View Details

    Schizophrenia - Special Topics - Special Topics Evolving Market Dynamics In Schizophrenia US

    The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primaril...

    View Details

    Schizophrenia - Special Topics - Special Topics: Agitation In Bipolar And Schizophrenia (US)

    Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or...

    View Details